Reducing Progression Rate of Age-Related Macular Degeneration

December 2021

AMD is the leading cause of blindness in the developed world for people over 50.
Disclaimer

This presentation has been prepared by Nova Eye Medical Limited (ASX: EYE). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any statement, estimates, opinions or other information contained in the presentation. This presentation may contain forward looking statements. These forward-looking statements have been made based upon Nova Eye Medical’s expectations and beliefs concerning future developments and their potential effect on Nova Eye Medicals (and its controlled entities) and are subject to risks and uncertainty which are, in many instances, beyond Nova Eye Medical’s control. No assurance is given that future developments will be in accordance with Nova Eye Medical’s expectations. Actual results could differ materially from those expected by Nova Eye Medical. This presentation does not constitute an offer to sell or a solicitation or an offer to purchase any security or financial product or service. Any such offer or solicitation shall be made only pursuant to a Product Disclosure Statement, Information Memorandum, Prospectus or other offer document relating to a financial product or service. Past performance is not necessarily indicative of future results and no person guarantees the performance of any financial product or service or the amount or timing of any return from it. There can be no assurance that the financial product or service will achieve any targeted return, that asset allocations will be met or that the financial product or service will be able to implement its investment strategy and investment approach or achieve its investment objective. The information contained in this presentation is not intended to be relied upon as advice to investors or potential investors, who should consider seeking independent professional advice depending upon their specific investment objectives, financial situation or particular needs.
Age-Related Macular Degeneration
Reducing Progression Rate of AMD

AMD is the leading cause of blindness in the developed world for people over 50

AMD in its late stage has two forms: “Wet” (choroidal neovascularization) and “Dry” (geographic atrophy)

Currently drugs provide temporary visual recovery and stabilization for patients with “Wet” AMD. There is no treatment for “Dry” AMD and patients with intermediate AMD take vitamins

Expenditure on such pharmaceuticals is largest spend in the health care systems of developed countries

Global spend on pharmaceuticals US$5.7billion and on vitamins for eye health US$2.4billion

2RT® to be used 2x per year for treatment of certain patients with intermediate AMD before the patient progresses to late stage AMD

1 “Eyes on the future – A clear look at AMD”. Deloitte Access Economics, 2011. 2 Highlight on Australian Pharmaceutical Benefits scheme year to 30 June 2020 spend on Aflibercept and Ranibizumabs A$577m. Highest on USA Medicare USA Department of Health, August 2018, $2.2bn. 3 Edison Group report Sept. 2020. 4 Reported in PRN Newswire 5 October 2020, supplements for AMD represents the largest share. 5 Based on a post hoc analysis LEAD Study
Intermediate Age-Related Macular Degeneration

AMD in its early or intermediate stage is based on the number and size of “drusen”.

Drusen are deposits that accumulate between the pigmented layer of the retina called the retina pigment endothelium (RPE) and a more outer layer called Bruch’s Membrane (“BM”).

These deposits inhibit the flow of nutrients to the retina. The size and extent of drusen in the macular have been shown to increase the risk of AMD progression.

Intermediate AMD is characterized by large drusen and medium drusen with pigmentary abnormalities. These patients are at significant risk for developing AMD both Wet and Dry.

Currently there are no treatments for patients with Intermediate AMD. Vitamins and nutritional supplements is the recommended standard of care¹, ².

1. Macular Degeneration Foundation Australia recommendation pamphlet “Nutrition for AMD”.
2. USA National Eye Institute AREDS/AREDS 2 study concluded that supplements reduces the rate of progression from intermediate AMD to advanced AMD by 25%
2RT® - Subthreshold Nanosecond Laser

2RT® is a rejuvenative retinal laser therapy that utilizes a nanosecond laser pulse and unique pixelated laser beam profile.

“Based on the LEAD⁠¹ study outcomes, 2RT® is currently a leading candidate treatment in the world for slowing the progression of patients with intermediate AMD to either late stage Wet or Dry AMD.”


1. LEAD study - LEAD (Laser Intervention in Early age related macular Degeneration), 292-person study conducted from 2012-2018 with follow up through to 2020.
Lasers were first used in ophthalmology in the mid 1960s. They relied on heating and destroying tissue for therapeutic effect. In the 1990’s it was found that thermal lasers hastened AMD progression and use was stopped.

Original work on subthreshold short pulse lasers that do not rely on heat, rather, generating enhanced up regulation of the natural biochemical cleaning mechanism which fails in ageing

Early 2000’s

Mid 2000’s

Development of subthreshold nanosecond laser (2RT®) with unique beam profile and impact on retinal cells.

Pre-clinical trials and laboratory work to determine safety for human studies.

2008 – 2010

2008 – 2010

50 person pilot study completed demonstrates safety.

2010 – 2012

Studies on method of action continue

2012 – 2012

2012 – 2020

2012 – 2020

2012 – 2021

2012 – 2021

Dec 2021

LEAD RCT – 292 person study in Europe and Australia demonstrates safety and promising efficacy in certain patients for up to 5 years from initial treatment.

Study protocol developed for USA based study to confirm LEAD results.

Study protocol developed for USA based study to confirm LEAD results.

1. Based on a post hoc analysis reported within “Subthreshold Nanosecond Laser Intervention in Age-Related Macular Degeneration - The LEAD Randomized Controlled Clinical Trial” Robyn H. Guymer, MBBS, PhD, et al and published in peer reviewed journal *Ophthalmology* of the American Academy of Ophthalmology


University College London, Institute of Ophthalmology, Professor John Marshall, Dr Ali Hussain

Centre for Eye Research Australia

University of Melbourne

Centre for Eye Research Australia

AlphaRET & University College London, Institute of Ophthalmology, Professor John Marshall, Dr Ali Hussain
2RT® for intervention in AMD progression in certain patients

Intervention concept schematic based on a post hoc analysis reported within “Subthreshold Nanosecond Laser Intervention in Age-Related Macular Degeneration - The LEAD Randomized Controlled Clinical Trial” Robyn H. Guymer, MBBS, PhD, et al and published in peer reviewed journal Ophthalmology of the American Academy of Ophthalmology
2RT® has a unique method of action

2RT® stimulates a process of cell division and production of new cell growth and the associated release of membrane cleaning enzymes, which improves permeability of Bruch’s membrane in the inner retina and thereby restores the transport of fluid across Bruch’s membrane.

2RT® pixelated beam profile selectively ablates multiple individual RPE cells within the 400 micron beam diameter.
Randomised Control Study Completed Demonstrates Efficacy & Safety in Certain Patients

LEAD (Laser Intervention in Early age-related macular Degeneration), 292-person study conducted from 2012-2018 with follow up through to 2020 showed 76%\(^{(1)}\) of patients in the study had a 77%\(^{(1)}\) reduction in progression to late stage AMD over thirty six months of treatment, an effect that endured for 24 months after treatment ceased.

The LEAD study did not meet its primary end points, but it has been lauded as a well-conducted study which has provided strong evidence of safety, the potential efficacy of 2RT and an understanding of the natural history of AMD. LEAD provides a sound foundation for a follow up study.

The investigators noted the fact that 24% of patients in the study had critical phenotype of retinal drusen, known as reticular pseudodrusen (RPD), and that these patients were negatively impacted by the laser treatment. This neutralised the outcome for the total study population\(^{(1)}\).

\(^{(1)}\) Based on *a post hoc* analysis reported within “Subthreshold Nanosecond Laser Intervention in Age-Related Macular Degeneration - The LEAD Randomized Controlled Clinical Trial” Robyn H. Guymer, MBBS, PhD, et al and published in peer reviewed journal *Ophthalmology* of the American Academy of Ophthalmology
2RT® Roadmap Pivotal Study

- PRE-CLINICAL WORK
- PILOT CLINICAL TRIAL
- CE MARK (iAMD) APPROVED FOR SALE IN AUST, NZ & EUROPE
- EFFICACY & SAFETY DEMONSTRATION CLINICAL STUDY (“LEAD”)
- PROTOCOL PREPARATION FOR PIVOTAL USA STUDY TO CONFIRM LEAD
- USA FDA INVESTIGATIONAL DEVICE EXEMPTION APPROVAL
- PIVOTAL USA STUDY
Global Unmet Need

Estimated population with Intermediate AMD treatable with 2RT® (market per year)

- USA: 5.3 million
- Europe: 8.2 million
- Other developed nations: 3.0 million
- Japan: 2.2 million
- China: 13.0 million
- LATAM and ROW: 23.2 million

Estimated 54.9 million people with Intermediate AMD treatable with 2RT®

Patients who do not meet 2RT® treatment criteria

2. Company estimate based on outcome of post hoc from LEAD study.
Estimated Revenue Opportunity for 2RT®

Subject to the completion of a pivotal study or similar to confirm results of the LEAD study (77% reduction in rate of progression to late-stage AMD in select patients with iAMD) the opportunity is very large.

Global annual revenue

US$600 million

Number of people worldwide with iAMD¹

Procedure fee-based revenue model³

LEAD protocol: 2x treatments per year²

Conservative 10% adoption rate by surgeons globally³

Business model comprising of capital equipment sale and procedure fee has corollary with laser vision correction technology, which was launched in the US in the early 2000s by start-up companies.

Tom Spurling
Managing Director
W: +61 8 8362 0193
E: tspurling@nova-eye.com

Mark Flynn
Investor Relations
M: +61 416 068 733
E: mflynn@nova-eye.com
Publication of positive five-year patient follow-up data from a sub-study analysis of the LEAD Trial in Ophthalmology Retina.1

A randomised, controlled multi-centre trial conducted in 292 patients during 2012-2018, the LEAD Trial assessed the efficacy of 2RT® at three years in patients with intermediate age-related macular degeneration.

Importantly, the LEAD Trial was the first time any form of Intervention had been reported to demonstrate a promising clinical response in selected patients with intermediate-stage AMD (iAMD).

In the published five-year post-LEAD review, which enrolled a total of 222 patients (76%) from the LEAD Trial, patients were split equally between the 2RT® treatment group (“2RT® Group” or “SNL”) and the non-treatment group (“Sham Group”).

Figure (right) plots the results of the LEAD Trial and the five-year post-LEAD review and demonstrates the difference in the rate of disease progression between the 2RT® Group (“SNL”) and the Sham Group in patients without coexistent reticular pseudodrusen or RPD².

---

(1) Guymer et al., 2021. Sub Subthreshold Nanosecond Laser in Age-Related Macular Degeneration: Observational Extension Study to the LEAD Clinical Trial. ACTRN 12612000704897

(2) RPD is a key biomarker of retinal pigment epithelium (RPE) dysfunction and has a high association with progression to late-stage AMD.